Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov 9;9(11):e05057.
doi: 10.1002/ccr3.5057. eCollection 2021 Nov.

Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy

David Bobrowski  1 , Reha Kumar  1 , Peter E Wu  1   2 , Lauren Lapointe-Shaw  1   3
Affiliations
Case Reports

Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy

David Bobrowski et al. Clin Case Rep. .

Erratum in

  • ERRATUM.
    [No authors listed] [No authors listed] Clin Case Rep. 2021 Nov 25;9(11):e05137. doi: 10.1002/ccr3.5137. eCollection 2021 Nov. Clin Case Rep. 2021. PMID: 34853690 Free PMC article.

Abstract

Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half-lives, the typical duration used to guide pre-operative medication recommendations.

Keywords: diabetes; euglycemic diabetic ketoacidosis; sodium‐glucose cotransporter 2 inhibitors.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest.

References

    1. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638‐1642. 10.2337/dc15-1380 - DOI - PubMed
    1. INVOKANA: HIGHLIGHTS OF PRESCRIBING INFORMATION . US Food and Drug Administration. 2020. https://www.janssenlabels.com/package‐insert/product‐monograph/prescribi...
    1. Ata F, Yousaf Z, Khan AA, et al. SGLT‐2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep. 2021;11(1). 10.1038/s41598-021-89752-w - DOI - PMC - PubMed
    1. Jeon JY, Kim SK, Kim KS, et al. Clinical characteristics of diabetic ketoacidosis in users and non‐users of SGLT2 inhibitors. Diabetes Metab. 2019;45(5):453‐457. 10.1016/j.diabet.2019.01.001 - DOI - PubMed
    1. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans? Diabetes. 2012;61(9):2199‐2204. 10.2337/db12-0052 - DOI - PMC - PubMed

Publication types

LinkOut - more resources